What's Going On With Medical Technology Company Motus GI's Shares Today?

Motus GI Holdings, Inc. MOTS said that Pure-Vu EVS Gastro was successfully used in the first procedure since receiving FDA clearance.

The case was completed by Dr. Brian Hanson, Gastroenterologist and Associate Professor of Medicine at the University of Minnesota.

The Pure-Vu EVS Gastro, which received FDA clearance in late October 2023, opens the critically important upper gastrointestinal (GI) portion of the market and access to the high acuity patients who suffer from upper GI bleeding.

"We were pleased by the Pure-Vu EVS Gastro's easy setup. I am pleased by the product's performance and look forward to using it in future cases," said Hanson.

The Pure-Vu EVS Gastro builds off the success of the patented and proprietary pulsed vortex irrigation and smart sense suction used in the colon device and has been enhanced to target blood, blood clots, and other debris in the upper GI tract. 

Price Action: MOTS shares are trading lower by 1.82% to $3.48 on the last check Friday.